The Eastern Cooperative Oncology Group (ECOG) has recently reviewed the outcome for more than 1,400 patients with previously untreated AML entered on five successive clinical trials.5,6 Each trial included daunorubicin and cytarabine for induction. Successive trials in this analysis included postremission therapy with increasingly more intensive consolidation. Among 1,414 patients,62% achieved CR, but 76% have relapsed or died. The overall survival (OS) rate for all patients at 5 years is only 15%. Patients aged 55 years or older fared particularly poorly. The 5-year OS rate was 9%33% for patients less than 55 years of age and 6%-15% for patients aged 55 years and older.5,6 Among patients less than age 55 years, both the DFS and OS increased with more intensive postremission strategies.